Neurothera Labs Announces Results of AGM

Core Points - Neurothera Labs Inc. held its annual and special meeting of shareholders on January 8, 2026, where key decisions were made regarding the company's governance and future plans [1] Group 1: Shareholder Decisions - All nominee directors listed in the management information circular dated December 4, 2025, were elected as directors [2] - Shareholders voted to appoint Dale Matheson Carr-Hilton Labonte LLP as auditors for the upcoming year and authorized the directors to fix their remuneration [2] - A consolidation of common shares was authorized, allowing for a potential consolidation of one post-consolidation share for up to one hundred pre-consolidation shares, subject to the directors' discretion and market conditions [3] - The adoption of a 20% fixed equity incentive plan was approved, pending final approval from the TSX Venture Exchange [4] Group 2: Company Overview - Neurothera Labs Inc. is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations [5]